MELANOMA ADJUVANT TREATMENT: current insight and clinical features

Carmine D Aniello, Giuseppina Della Vittoria Scarpati, Chiara Della Pepa, Salvatore Pisconti, Vincenzo Montesarchio, Nicolas Wernert, Mayra Rachele Zarone, Michele Caraglia, Gaetano Facchini, Carla Cavaliere

Research output: Contribution to journalArticlepeer-review


Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. Despite an optimal surgery management, the risk of a local and systemic relapse remains high, particularly in high-risk patients (node-positive or node-negative T3b, T4 a/b). We conducted a systematic review of the main published and ongoing phase I/II/III trials between 2000 and June 2015 on the adjuvant treatment of cutaneous melanoma. The IFN remains the only option currently available for this aim. Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of disease free survival (DFS), while data regarding OS are pending. Recent advances in the understanding of the biology of melanoma result in the identification of MAPK pathway role in the melanoma development Based on these features, B-RAF inhibitors and their combination with immunotherapy could represent the upcoming therapeutic strategy.

Original languageEnglish
JournalCurrent Cancer Drug Targets
Publication statusPublished - 2018


Dive into the research topics of 'MELANOMA ADJUVANT TREATMENT: current insight and clinical features'. Together they form a unique fingerprint.

Cite this